HIV Integrase

Enzyme of the HUMAN IMMUNODEFICIENCY VIRUS that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene.

Also Known As:

HIV Integration Protein; p31 Integrase Protein, HIV; p31 Integrase Protein, Human Immunodeficiency Virus; p31 pol Gene Product, HIV; p31 pol Gene Product, Human Immunodeficiency Virus; Integrase, HIV; Integration Protein, HIV

Networked: 62 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Nair, Vasu: 4 articles (08/2014 - 05/2002)
2.	Debyser, Zeger: 2 articles (01/2019 - 07/2002)
3.	Coleman, Paul J: 2 articles (01/2017 - 02/2015)
4.	Grobler, Jay: 2 articles (01/2017 - 02/2015)
5.	Hazuda, Daria J: 2 articles (01/2017 - 09/2008)
6.	Sanders, John M: 2 articles (01/2017 - 02/2015)
7.	Mishra, Sanjay: 2 articles (08/2014 - 10/2011)
8.	Okello, Maurice: 2 articles (08/2014 - 10/2011)
9.	Neamati, N: 2 articles (07/2001 - 06/2001)
10.	Pommier, Y: 2 articles (07/2001 - 06/2001)

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS) 03/01/2009 - "HIV integrase has emerged as a promising target for discovery of agents against the acquired immunodeficiency syndrome (AIDS) pandemic. " 08/01/2001 - "Several classes of compounds have been screened and further scrutinised for their inhibitory properties against the HIV integrase; however, there are currently no useful inhibitors available clinically for the treatment of AIDS patients. " 06/04/2001 - "Discovery of novel inhibitors of HIV integrase is of considerable significance in approaches to the development of therapeutic agents against AIDS. " 07/01/2001 - "For this reason, HIV integrase (IN) has become an important target for the development of new AIDS therapeutics. " 05/01/1997 - "HIV integrase: a target for AIDS therapeutics."
2.	HIV Infections (HIV Infection) 01/01/2008 - "Recent progress in the development of inhibitors of human immunodeficiency virus (HIV) integrase for the management of HIV infection." 03/01/2005 - "HIV integrase is a rational target for treating HIV infection and preventing AIDS. " 11/26/2021 - "The long-acting parenteral formulation of the HIV integrase inhibitor cabotegravir (GSK744) is currently being developed to prevent HIV infections, benefiting from infrequent dosing and high efficacy. " 02/01/2015 - "Raltegravir is a small molecule HIV integrase strand-transfer inhibitor approved for the treatment of HIV infection with twice-daily administration. " 01/01/2014 - "Dolutegravir (DTG) is an HIV integrase strand transfer inhibitor approved for use in combination with other antiretrovirals for the treatment of HIV-infection in adults and adolescents. "
3.	Infections 10/22/2022 - "A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection." 10/07/2021 - "Briefly, the suggested cocktail of drugs should contain (i) latency reversal agents to promote the latency reversal process in replication-competent reservoir cells, (ii) pro-apoptotic and anti-autophagy drugs to induce death of infected cells through various pathways, and finally (iii) drugs that eliminate new cycles of infection by prevention of HIV attachment to host cells, and by HIV integrase inhibitor drugs. " 01/01/2019 - "Despite the progress in the discovery of antiretroviral compounds for treating HIV-1 infection by targeting HIV integrase (IN), a promising and well-known drug target against HIV-1, there is a growing need to increase the armamentarium against HIV, for avoiding the drug resistance issue. " 02/01/2017 - "Preliminary molecular modelling studies carried out on the two analogues showed interactions near the active site of HIV integrase; however, in comparison with raltegravir, the biological evaluation confirmed that CAA-1 and CAA-2 were unable to inhibit infection at lower concentration." 09/25/2008 - "The good profile of Raltegravir has enabled its progression toward the end of phase III clinical trials for the treatment of HIV-1 infection and culminated with the FDA approval as the first HIV-integrase inhibitor for the treatment of HIV-1 infection."
4.	Neural Tube Defects (Exencephaly) 01/01/2019 - "SIGNIFICANCE STATEMENT: Preliminary analysis of ongoing birth surveillance study identified evidence of potential increased risk for neural tube defects (NTDs) in newborns associated with exposure to the HIV integrase inhibitor dolutegravir at the time of conception; folate deficiency is a common cause of NTDs. "
5.	Human Influenza (Influenza) 01/01/2022 - "Compounds that target TMID enzymes, such as HIV integrase and influenza endoribonuclease, have been successfully developed for clinical use. " 01/01/2016 - "The hydroxypyridonecarboxylic acid scaffold has been implicated in inhibiting homologous HIV integrase (IN) and influenza endonuclease via metal chelation. "

Related Drugs and Biologics

1.	Raltegravir Potassium
2.	dolutegravir
3.	cabotegravir
4.	Antiviral Agents (Antivirals)
5.	elvitegravir
6.	imidazole mustard (BIC)
7.	bictegravir
8.	Folic Acid (Vitamin M)
9.	Enzymes
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections